CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 148 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.79 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $61,503,750 | +27.6% | 4,125,000 | -6.3% | 0.14% | +32.4% |
Q2 2023 | $48,194,147 | +25.6% | 4,401,292 | +0.0% | 0.10% | +22.1% |
Q1 2023 | $38,362,768 | +1123.7% | 4,399,400 | +779.9% | 0.09% | +1128.6% |
Q4 2022 | $3,135,000 | +79.1% | 500,000 | 0.0% | 0.01% | +75.0% |
Q3 2022 | $1,750,000 | +18.6% | 500,000 | 0.0% | 0.00% | +33.3% |
Q2 2022 | $1,475,000 | -68.4% | 500,000 | -66.7% | 0.00% | -66.7% |
Q1 2022 | $4,665,000 | -4.8% | 1,500,000 | +3.4% | 0.01% | 0.0% |
Q4 2021 | $4,901,000 | -7.4% | 1,450,000 | 0.0% | 0.01% | -10.0% |
Q3 2021 | $5,293,000 | -16.3% | 1,450,000 | 0.0% | 0.01% | -16.7% |
Q2 2021 | $6,322,000 | -4.0% | 1,450,000 | 0.0% | 0.01% | -7.7% |
Q1 2021 | $6,583,000 | -20.9% | 1,450,000 | 0.0% | 0.01% | -27.8% |
Q4 2020 | $8,323,000 | -20.7% | 1,450,000 | 0.0% | 0.02% | -30.8% |
Q3 2020 | $10,498,000 | +20.3% | 1,450,000 | -42.0% | 0.03% | +18.2% |
Q2 2020 | $8,725,000 | +293.0% | 2,500,000 | +66.7% | 0.02% | +214.3% |
Q1 2020 | $2,220,000 | -24.5% | 1,500,000 | 0.0% | 0.01% | 0.0% |
Q4 2019 | $2,940,000 | -61.7% | 1,500,000 | 0.0% | 0.01% | -63.2% |
Q3 2019 | $7,680,000 | -28.5% | 1,500,000 | 0.0% | 0.02% | -29.6% |
Q2 2019 | $10,740,000 | -66.7% | 1,500,000 | -38.1% | 0.03% | -66.7% |
Q1 2019 | $32,204,000 | +89.4% | 2,425,000 | +12.3% | 0.08% | +72.3% |
Q4 2018 | $17,000,000 | -22.3% | 2,160,150 | +9.4% | 0.05% | -4.1% |
Q3 2018 | $21,883,000 | -34.1% | 1,975,000 | -20.2% | 0.05% | -35.5% |
Q2 2018 | $33,215,000 | -26.4% | 2,475,000 | -28.8% | 0.08% | -27.6% |
Q1 2018 | $45,140,000 | +49.6% | 3,475,000 | +6.0% | 0.10% | +54.4% |
Q4 2017 | $30,172,000 | +21.7% | 3,279,526 | +6.7% | 0.07% | +13.3% |
Q3 2017 | $24,785,000 | +133.8% | 3,075,000 | +67.1% | 0.06% | +130.8% |
Q2 2017 | $10,599,000 | +34.0% | 1,840,044 | 0.0% | 0.03% | +30.0% |
Q1 2017 | $7,912,000 | +553.3% | 1,840,044 | +162.9% | 0.02% | +566.7% |
Q4 2016 | $1,211,000 | -10.8% | 700,000 | 0.0% | 0.00% | -25.0% |
Q3 2016 | $1,358,000 | -15.1% | 700,000 | -23.8% | 0.00% | 0.0% |
Q2 2016 | $1,599,000 | -30.3% | 919,200 | -45.9% | 0.00% | -33.3% |
Q1 2016 | $2,295,000 | -20.1% | 1,700,000 | 0.0% | 0.01% | -25.0% |
Q4 2015 | $2,873,000 | -12.9% | 1,700,000 | 0.0% | 0.01% | -11.1% |
Q3 2015 | $3,298,000 | +22.6% | 1,700,000 | +70.0% | 0.01% | +28.6% |
Q2 2015 | $2,690,000 | -61.1% | 1,000,000 | 0.0% | 0.01% | -58.8% |
Q1 2015 | $6,920,000 | +97.2% | 1,000,000 | +180.0% | 0.02% | +88.9% |
Q4 2014 | $3,510,000 | – | 357,085 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |